azomycin has been researched along with lansoprazole in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gisbert, JP | 1 |
| Ho, B; Ling, KL; Luman, W; Ng, HS | 1 |
| Mahachai, V; Sirimontaporn, N; Thong-Ngam, D; Tumwasorn, S; Vilaichone, RK | 1 |
1 review(s) available for azomycin and lansoprazole
| Article | Year |
|---|---|
[Lansoprazole: a review of its role in Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Nitroimidazoles; Omeprazole; Penicillins | 1999 |
1 trial(s) available for azomycin and lansoprazole
| Article | Year |
|---|---|
Efficacy of a nitroimidazole containing tripletherapy regime in Singapore.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nitroimidazoles; Omeprazole; Singapore; Tinidazole | 2001 |
1 other study(ies) available for azomycin and lansoprazole
| Article | Year |
|---|---|
Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Biopsy; Breath Tests; Chi-Square Distribution; Clarithromycin; DNA, Bacterial; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastroscopy; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nitroimidazoles; Odds Ratio; Point Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Proton Pump Inhibitors; Ribotyping; Risk Assessment; Risk Factors; RNA, Ribosomal, 23S; Thailand; Time Factors; Treatment Outcome | 2011 |